...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Potential Drug-Drug Interactions in Cardiothoracic Intensive Care Unit of a Pulmonary Teaching Hospital
【24h】

Potential Drug-Drug Interactions in Cardiothoracic Intensive Care Unit of a Pulmonary Teaching Hospital

机译：肺教学医院心胸重症监护病房中潜在的药物相互作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Little is known about clinically significant drug-drug interactions (DDIs) in respiratory settings. DDIs are more likely to occur in critically ill patients due to complex pharmacotherapy regimens and organ dysfunctions. The aim of this study was to identify the pattern of potential DDIs (pDDIs) occurring in cardiothoracic intensive care unit (ICU) of a pulmonary hospital. A prospective observational study was conducted for 6 months. All pDDIs for admitted patients in cardiothoracic ICU were identified with Lexi-Interact program and assessed by a clinical pharmacologist. The interacting drugs, reliability, mechanisms, potential outcomes, and clinical management were evaluated for severe and contraindicated interactions. The study included 195 patients. Lung cancer (14.9%) was the most common diagnosis followed by tracheal stenosis (14.3%). The rate of pDDIs was 720.5/100 patients. Interactions were more commonly observed in transplant patients. 17.7% of pDDIs were considered as severe and contraindicated interactions. Metabolism (54.8%) and additive (24.2%) interactions were the most frequent mechanisms leading to pDDIs, and azole antifungals and fluoroquinolones were the main drug classes involved. The pattern of pDDIs in cardiothoracic ICU differs from other ICU settings. Specialized epidemiological knowledge of drug interactions may help clinical practitioners to reduce the risk of adverse drug events.
机译：对于呼吸系统临床意义重大的药物相互作用（DDI）知之甚少。由于复杂的药物治疗方案和器官功能障碍，重症患者更容易发生DDI。这项研究的目的是确定在肺科医院的心胸重症监护病房（ICU）中发生的潜在DDI（pDDI）模式。进行了为期6个月的前瞻性观察研究。通过Lexi-Interact程序鉴定了心胸ICU入院患者的所有pDDI，并由临床药理学家进行评估。对相互作用的药物，可靠性，机理，潜在的结果和临床管理进行了评估，以评估严重和禁忌的相互作用。该研究包括195名患者。肺癌（14.9％）是最常见的诊断，其次是气管狭窄（14.3％）。 pDDI发生率为720.5 / 100名患者。相互作用在移植患者中更常见。 17.7％的pDDI被认为是严重且禁忌的相互作用。代谢（54.8％）和加性（24.2％）相互作用是导致pDDI的最常见机制，并且吡咯类抗真菌药和氟喹诺酮类药物是涉及的主要药物类别。心胸ICU中pDDI的模式不同于其他ICU设置。药物相互作用的专门流行病学知识可能有助于临床医生减少药物不良事件的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号